J and J Snack Foods Newswire

J and J Snack Foods Newswire

Comprehensive Real-Time News Feed for J and J Snack Foods.

Results 1 - 20 of 608 in J and J Snack Foods

  1. UPDATE 4-FDA staff backs biosimilar to Remicade; J&J and AbbVie fallRead the original story w/Photo

    2 hrs ago | Reuters

    A man walks past a logo of Celltrion Inc in front of the plant in Incheon, west of Seoul April 26, 2013. U.S. Food and Drug Administration staff members on Friday said Celltrion Inc's biosimilar form of Johnson & Johnson's Remicade arthritis drug appeared "highly similar" to the widely used branded product.

    Comment?

  2. Celltrion's Copy of J&J's Remicade Gets FDA Staff SupportRead the original story

    8 hrs ago | The Washington Post

    Celltrion Inc.'s experimental copy of Johnson & Johnson's best-selling arthritis treatment Remicade gained support from U.S. regulators in a staff report released on Friday. If eventually approved for sale, Celltrion's drug, called CT-P13, will be the second-ever in the U.S. from a class of lower-cost versions of brand-name biotechnology drugs known as biosimilars.

    Comment?

  3. J&J, ViaCyte testing possible diabetes cureRead the original story w/Photo

    Yesterday | Salt Lake Tribune

    Johnson & Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could fix the life-threatening hormonal disorder. They've already begun testing it in a small number of diabetic patients.

    Comment?

  4. J&J, ViaCyte test Type 1 diabetes cureRead the original story w/Photo

    Yesterday | Philly.com

    Johnson & Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could fix the life-threatening hormonal disorder. They've already begun testing it in a small number of diabetic patients.

    Comment?

  5. Johnson & Johnson, ViaCyte testing possible diabetes cureRead the original story w/Photo

    Yesterday | KOLD-TV Tucson

    By LINDA A. JOHNSON AP Business Writer Johnson & Johnson, continuing its long quest for a Type 1 diabetes cure, is joining forces with biotech company ViaCyte to speed development of the first stem cell treatment that could fix the life-threatening hormonal disorder. They've already begun testing it in a small number of diabetic patients.

    Comment?

  6. Achillion Announces Appointments Of As General Counsel And As Head Of Regulatory AffairsRead the original story

    Tuesday | BioSpace

    Achillion Pharmaceuticals, Inc. today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016.

    Comment?

  7. Will Johnson & Johnson's Plan To Retool Its Medical Device Business Succeed?Read the original story

    Thursday Jan 28 | BioSpace

    Big changes are afoot in the medical device industry, and Johnson & Johnson is in the driver's seat. When the largest among medical device companies makes a move, the industry tends to stop and pay attention.

    Comment?

  8. VC Renaissance: Index Ventures spin off Medicxi launches GSK and J&J backed a 210m fundRead the original story w/Photo

    Wednesday | Drug Researcher

    The venture capital group - which will be managed by Francesco De Rubertis, David Grainger, Kevin Johnson and MichA le Ollier - said the fund will " predominantly invest in Europe " and focus on developers working in areas of unmet medical need. Medicxi Ventures told us that, rather than investing in any particular therapeutic areas, if follows an " asset-centric " and " will invest in companies with just one or two assets rather than multiple programmes.

    Comment?

  9. Achillion Announces Appointments of Martha Manning as General Counsel ...Read the original story w/Photo

    Wednesday | GlobeNewswire

    Achillion Pharmaceuticals, Inc. today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016.

    Comment?

  10. VC Renaissance: Index Ventues spin off Medixci launches GSK and J&J backed a 210m fundRead the original story w/Photo

    Tuesday | Drug Researcher

    The venture capital group - which will be managed by Francesco De Rubertis, David Grainger, Kevin Johnson and MichA le Ollier - said the fund will " predominantly invest in Europe " and focus on developers working in areas of unmet medical need. Medixci Ventures told us that, rather than investing in any particular therapeutic areas, if follows an " asset-centric " and " will invest in companies with just one or two assets rather than multiple programmes.

    Comment?

  11. Sony Consolidates Much of its Media After Global ReviewRead the original story w/Photo

    Thursday Jan 28 | Advertising Age

    Sony has consolidated much of its media agency business, with the bulk landing at MediaCom and UM. The global review spanned Sony Pictures, Sony Electronics, Sony Mobile Communications, Sony Music and Playstation.

    Comment?

  12. GSK invests in another startup fund along with J&JRead the original story w/Photo

    Tuesday Feb 2 | Local Tech Wire

    GlaxoSmithKline, which is under growing investor pressure to improve its financials, is investing alongside Johnson & Johnson in another startup fund. For the second time in a week, GSK moves to back new and emerging ventures in hopes of driving future growth....

    Comment?

  13. GSK and J&J back $1 billion biotech spin-off from Index VenturesRead the original story w/Photo

    Tuesday Feb 2 | Silicon Alley Insider

    Index Ventures, an early investor in technology hits like Skype and Dropbox, is spinning off its biotech portfolio into a new $1 billion business, with backing from drug giants GlaxoSmithKline The new Medicxi Ventures business will be led by the existing life sciences team from Index Ventures and includes all the current biotech portfolio companies. Medicxi said on Tuesday it had raised 210 million euros for a new fund focused on early-stage life sciences investments in Europe, with GSK and J&J each contributing 25 percent.

    Comment?

  14. Discovery Labs Announces Appointment of New Chief Executive Officer...Read the original story

    Monday Feb 1 | Freshnews

    Discovery Laboratories, Inc. , a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced the appointment of a new Chief Executive Officer and has provided an update on its AEROSURF phase 2 program. Craig Fraser has been appointed as the Company's President and Chief Executive Officer, effective immediately.

    Comment?

  15. Atherectomy Devices Market (2015 - 2021): Global Market Study and AnalysisRead the original story w/Photo

    Friday Jan 29 | SBWire

    Atherectomy is a procedure performed to remove the atherosclerotic plaque from the arteries. This procedure is performed to improve the blood flow through the diseased artery and to reduce the blood pressure exerted on the lumen .

    Comment?

  16. J&J Should Not Consider Splitting Its BusinessRead the original story w/Photo

    Thursday Jan 28 | Seeking Alpha

    I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.

    Comment?

  17. How to Trade 6 Dow Components on Jim Cramera s 'Anointed' List of StocksRead the original story w/Photo

    Thursday Jan 28 | TheStreet.com

    Weakness at the close of 2014 made the stock one of the "Dogs of the Dow" for 2015. The stock was the fourth-best performer of the Dow 30 in 2015, with a gain of 23.3%.

    Comment?

  18. Investor pressures J&J to consider split up: sourcesRead the original story

    Wednesday Jan 27 | WNFL-AM Green Bay

    Artisan Partners, a major shareholder in Johnson & Johnson, has urged several activists to pressure the consumer products giant to consider major changes that include a potential split, according to sources and documents. Artisan has asked Johnson & Johnson's management to consider separating its three divisions - consumer products, pharmaceuticals and medical devices - into standalone companies in hopes of unlocking up to $90 billion in enterprise value, said sources familiar with the matter.

    Comment?

  19. Contravisory Investment Management Decreases Stake in J & J Snack Foods CorpRead the original story w/Photo

    Wednesday Jan 27 | AmericanBankingNews.com

    Contravisory Investment Management decreased its stake in J & J Snack Foods Corp by 3.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission . The firm owned 2,298 shares of the company's stock after selling 80 shares during the period.

    Comment?

  20. J&J to Pay $120 Million in Its First Big Mesh SettlementRead the original story

    Wednesday Jan 27 | Bloomberg

    Johnson & Johnson has made its first serious move to settle thousands of lawsuits filed by women who fault the company's vaginal-mesh inserts for their injuries, according to people familiar with the matter. The medical-device maker agreed to pay more than $120 million to resolve 2,000 to 3,000 suits alleging women suffered organ damage and were left in constant pain by mesh surgical inserts that eroded in their bodies, according to three people who asked not to be named because they weren't authorized to speak publicly about the settlement.

    Comment?